Dr. Shaukat Iqbal

Home
Dr. Shaukat Iqbal

PROFESSOR

drshaukat@cust.edu.pk

+92-51-111-555-666

PROFILE SUMMARY

Currently, he is employed as a bioscience professor at Islamabad’s Capital University of Science and Technology. He agreed to take up the role of Director VIS at the same university in 2018 as an additional university commitment. For the past nine years, he has also served as the Cancer Cytogenetics Research Group’s (CCRG) research group leader. Based on his credentials, he earned doctorate and post-doctoral degrees in Europe and the US, respectively. As a specialist with extensive managerial knowledge in education management and research and development for more than three decades, he has improved and demonstrated his abilities in teaching & research. Prestigious institutions such as The University of North Carolina, The United States EPA, NC, National & Kapodestrain University of Athens, University of Qatar, Anglia Ruskin University and Cambridge, UK, and domestically in the tier-I National University (NUST) and CUST are among those with which he has had the pleasure of becoming acquainted. Furthermore, he has successfully supervised 5 PhD scholars, 21 MS theses, and around fifty FYP. It should be mentioned that he was awarded by HEC a NRUP research project that was worth 3.12 million rupees. Currently, he has an Accumulate Impact Factor of 117.9.

QUALIFICATION
PhD	Biochemistry and Molecular Biology	National & Kapodestrain University of Athens & Cancer Cytogenetics, Athens	2004
M.Sc	Cytogenetics	Sindh University, Pakistan	1998

TEACHING EXPERIENCE
Professor	Capital University of Science and Technology (CUST), Islamabad	Since – 2018
Associate Professor	Capital University of Science and Technology (CUST), Islamabad	2015 – 2018
Associate Professor	Qatar University	2014
Associate Professor	National University of Science & Technology, Islamabad	2012 – 2013
Associate Professor	Mohammad Ali Jinnah University, Islamabad	2007 – 2011

MANAGEMENT EXPERIENCE
Director	VIS, Capital University of Science & Technology, Islamabad	2018 – 2021
HoD	Research of PG & UG Lab in CUST	Since – 2016
Chairman	Acting Chairman BUTUMS	2004 – 2005

RESEARCH AREAS / INTERESTS
1.	Molecular Biology & Human Genetics
2.	Cancer Cytogenetics
3.	Comet Assay
4.	Micro-arrays Gene Expression & Data Analysis

RESEARCH SUPERVISION
1.	Ph.D.	Cytogenetic approach for the evaluation of mutagenic potential causes cancer
2.	Ph.D.	Molecular Characterization and Computational Analysis of Drug-Resistant Strains of Mycobacterium Tuberculosis
3.	Ph.D.	Prevalence of Different Cancer in Pakistani Population and their Causes
4.	Ph.D.	Molecular Characterization and Computational Analysis of Drug-Resistant Strains in Cancer
5.	Ph.D.	Causes of early development of Bladder Cancer in Pakistani Population
6.	Ph.D.	Pharmacogenomics Aspects of Inflammatory Biomarkers Including Brain Cancer – Glioma for Precision Cancer Medicine
7.	Ph.D.	Effect of Lung Cancer Cells Derived Exosomes on T Cells Proliferation
8.	MS	Investigating Molecular Transformations via CHEK2 Gene Transcript Profiling in Peripheral Blood Samples of Oldest Breast Cancer Women’s Pre- and Post-Tumor Excision Studies
9.	MS	Detection of Novel Mutations in Retinoblastoma by Using Bioinformatics Tools
10.	MS	PMS2 Gene Expression Profiling in the Peripheral Blood of Elder Women with Breast Carcinoma: A Pre-and Post-Operative Comparative Study
11.	MS	To Study the Incidence of Retinoblastoma in Islamabad & Rawalpindi Population & Parent Knowledge of Screening & Genetic Testing in Retinoblastoma
12.	MS	Prevalence of Brest Cancer in local population
13.	MS	Computational Analysis on the Role of GPM6A in Human Thyroid Cancer
14.	MS	In Silico Mining of RAS Gene Family Expression Data in Human Thyroid Cancer
15.	MS	Estrogen Fluctuation of Postmenopausal Risk to Breast Cancer in Pakistani Population
16.	MS	Breast Cancer Prevalence in twin cities of Pakistan
17.	MS	Genetic Analysis of Hereditary Polydactyly in Pakistani Families
18.	MS	Antimicrobial Susceptibility Pattern and Multidrug Resistance Status of Salmonella typhii in population of Rawalpindi
19.	MS	Clinical and Demographics Variables of Beta Thalassemia patients from Islamabad
20.	MS	Assessment of awareness concerning prophylaxis against COVID-19 in Pakistani population
21.	MS	Comparison of Spread of Covid-19 in Various Countries
22.	MS	Isolation and Antibacterial Activity of Bacteriocin Produced by Bacteria Isolated from Yogurt
23.	MS	Association of Interleukin (IL) Il-17A and IL-6 Gene Polymorphisms with Susceptibility to Tuberculosis
24.	MS	Dairy Probiotics: Analysis of their Microbiological and Functional Aspects.
25.	MS	Association of FTO gene polymorphisms with risk of type 2 diabetes: an updated meta-analysis
26.	MS	Interleukin 17a, 17F and 18 SNPs assosiation with asthma: a updated meta-analysis
27.	MS	Association of cytokine gene polymorphisms with the risk of cystic fibrosis: meta-analysis
28.	MS	Relationship among single nucleotide polymorphism of interleukin-4 and interleukin-18 and susceptibility to pulmonary tuberculosis in Pakistani population
29.	MS	Comparison of Biological evaluation of two different varieties of Cumin Seed Extracts
30.	MS	Correlation Between Social Stress Causing Factors (SSCFs) and Appetite Among the Students of Rawalpindi and Islamabad.
31.	MS	Association of TNF-α -308G/A gene polymorphism with the risk of Autoimmune diseases
32.	MS	Identify genetic loci influencing the recovery process using accurate phenotyping to produce the largest genome-wide association study in Atherosclerosis stroke recovery.
33.	MS	Biological Evaluation and Comparison Of Nigella sativa and Trachyspermum ammi.
34.	MS	Association of IL-1β and IL-17F gene polymorphism with susceptibility to TB patients in Pakistan
35.	MS	Causes and investigation of bladder cancer development in preliminary ages of Pakistan and their comparison with European countries
36.	MS	Use of low laser therapy to treat pain in various body parts focused on knee problem

SR.	JOURNAL PUBLICATIONS	YEAR
1	S. I. Malik, N. Ahmed, S. Jabeen, F. Rashid, N. Lal, M. Ali, A. Sattar, A. Ali, A. Ali, M. Arshad, Y. Fu et al., “Valuation of knowledge, attitude, practices of tuberculosis among the health care workers from Islamabad Pakistan,” Acta Tropica, vol. 257, p. 107317, 2024.	2024
2	H. Ahsan, M. Asghar, and S. I. Malik, “Potential diagnostic and drug target markers in glioblastoma,” Scientific Reports, vol. 14, no. 1, p. 7292, 2024.	2024
3	S. Hussain, H. Bokhari, X. Fan, S. I. Malik, S. Ijaz, M. A. Shereen, and A. Fatima, “MicroRNAs modulation in lung cancer: exploring dual mechanisms and clinical prospects.” Biocell, vol. 48, no. 3, pp. 403-413, 2024.	2024
4	H. Ahsan, S. I. Malik, F. A. Shah, H. A. El-Serehy, A. Ullah, and Z. A. Shah, “Celecoxib suppresses NF-κB p65 (Rela) and TNFα expression signaling in glioblastoma,” Journal of Clinical Medicine, vol. 12, no. 20, p. 6683, 2023.	2023
5	H. Ishaq, T. Ahmed, and S. I. Malik, “The association between stress factors and number of meals consumed per day in a sample of Pakistani students,” World Nutrition, vol. 14, no. 4, pp. 33–40, 2023.	2023
6	H. Ahsan and S. I. Malik, “NGS-mutational analysis of driver genes and TGFB1 with tumor suppressive and oncogenic roles in glioblastoma: An integrated approach with driver DBV3,” Genomics (PCGP), vol. 56, no. 04, pp. 102-125, 2023.	2023
7	S. Hussain and S. I. Malik, “Proliferative effects of lung cancer cells derived exosomes on T cells,” Brazilian Archives of Biology and Technology, vol. 65, p. e22210234, 2022.	2022
8	S. Hussain and S. Malik, “Effects of tumor derived exosomes on T cells markers expression,” Brazilian Journal of Biology, vol. 84, p. e250556, 2022.	2022
9	A. Sajid, M. S. Saeed, R. M. Malik, S. Fazal, S. Malik, and M. A. Kamal, “Prediction of secondary and tertiary structure and docking of RB1WT and RB1R661W proteins,” Current Biotechnology, vol. 11, no. 1, pp. 71–85, 2022.	2022
10	S. Arif, H. Saqib, M. Mubashir, S. I. Malik, A. Mukhtar, S. Saqib, S. Ullah, and P. L. Show, “Comparison of Nigella sativa and Trachyspermum ammi via experimental investigation and biotechnological potential,” Chemical Engineering and Processing-Process Intensification, vol. 161, p. 108313, 2021.	2021
11	S. Qiu, A. Munir, S. I. Malik, S. Khan, and A. Hassan, “Identification of differentially expressed genes and pathways crosstalk analysis in rheumatoid and osteoarthritis using next-generation sequencing and protein-protein networks,” Saudi Journal of Biological Sciences, vol. 28, no. 8, pp. 4656–4663, 2021.	2021
12	F. Butt, M. Yasinzai, S. I. Malik, and A. Munir, “Isolation and characterization of leishmanial adenine aminohydrolase as a drug target,” Current Computer-Aided Drug Design, vol. 17, no. 7, pp. 905–915, 2021.	2021
13	S. Hussain, A. Fatima, X.-X. Fan, and S. I. Malik, “The biological importance of cells secreted exosomes.” Pakistan Journal of Pharmaceutical Sciences, vol. 34, no. 6, pp. 2273-2279, 2021.	2021
14	S. Hussain, S. E. Z. Bokhari, X. X. Fan, and S. Iqbal, “The role of exosomes derived miRNA in cancer,” J of Pak Med Assoc, vol. 71, no. 7, pp. 1856–61, 2021.	2021
15	M. T. Khan, M. T. Zeb, H. Ahsan, A. Ahmed, A. Ali, K. Akhtar, S. I. Malik, Z. Cui, S. Ali, A. S. Khan et al., “SARS-CoV-2 nucleocapsid and Nsp3 binding: an in silico study,” Archives of Microbiology, vol. 203, pp. 59–66, 2021.	2021
16	A. Munir, S. I. Malik, and K. A. Malik, “De-novo ligand design against mutated Huntington gene by ligand-based pharmacophore modeling approach,” Current Computer-Aided Drug Design, vol. 16, no. 2, pp. 134–144, 2020.	2020
17	S. Hussain, Y.-J. Xie, D. Li, S. I. Malik, J.-C. Hou, E. L.-H. Leung, and X.-X. Fan, “Current strategies against COVID-19,” Chinese Medicine, vol. 15, pp. 1–12, 2020.	2020
18	M. T. Khan, A. C. Kaushik, Q. u. a. Rana, S. I. Malik, A. S. Khan, D.-Q. Wei, W. Sajjad, S. Ahmad, S. Ali, Ameenullah et al., “Characterization and synthetic biology of lipase from Bacillus amyloliquefaciens strain,” Archives of Microbiology, vol. 202, pp. 1497–1506, 2020.	2020
19	M. T. Khan and S. I. Malik, “Structural dynamics behind variants in pyrazinamidase and pyrazinamide resistance,” Journal of Biomolecular Structure and Dynamics, vol. 38, no. 10, pp. 3003–3017, 2020.	2020
20	M. T. Khan, S. Ali, M. T. Zeb, A. C. Kaushik, S. I. Malik, and D.-Q. Wei, “Gibbs free energy calculation of mutation in PNCA and RPSA associated with pyrazinamide resistance,” Frontiers in Molecular Biosciences, vol. 7, p. 52, 2020.	2020
21	M. T. Khan, A. C. Kaushik, L. Ji, S. I. Malik, S. Ali, and D.-Q. Wei, “Artificial neural networks for prediction of tuberculosis disease,” Frontiers in Microbiology, vol. 10, p. 395, 2019.	2019
22	M. T. Khan, S. I. Malik, S. Ali, N. Masood, T. Nadeem, A. S. Khan, and M. T. Afzal, “Pyrazinamide resistance and mutations in PNCA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan,” BMC Infectious Diseases, vol. 19, pp. 1–7, 2019.	2019
23	M. T. Khan, A. Khan, A. U. Rehman, Y. Wang, K. Akhtar, S. I. Malik, and D.-Q. Wei, “Structural and free energy landscape of novel mutations in ribosomal protein S1 (RPSA) associated with pyrazinamide resistance,” Scientific Reports, vol. 9, no. 1, p. 7482, 2019.	2019
24	M. T. Khan, A. C. Kaushik, A. I. Bhatti, Y.-J. Zhang, S. Zhang, A. J. Wei, S. I. Malik, and D. Q. Wei, “Marine natural products and drug resistance in latent tuberculosis,” Marine Drugs, vol. 17, no. 10, p. 549, 2019.	2019
25	M. T. Khan, M. Junaid, X. Mao, Y. Wang, A. Hussain, S. I. Malik, and D.-Q. Wei, “Pyrazinamide resistance and mutations L19R, R140H, and E144K in pyrazinamidase of Mycobacterium tuberculosis,” Journal of Cellular Biochemistry, vol. 120, no. 5, pp. 7154–7166, 2019.	2019
26	A. Munir, S. I. Malik, and K. A. Malik, “Proteome mining for the identification of putative drug targets for human pathogen Clostridium tetani,” Current Bioinformatics, vol. 14, no. 6, pp. 532–540, 2019.	2019
27	A. U. Rehman, M. T. Khan, H. Liu, A. Wadood, S. I. Malik, and H.-F. Chen, “Exploring the pyrazinamide drug resistance mechanism of clinical mutants T370P and W403G in ribosomal protein S1 of Mycobacterium tuberculosis,” Journal of Chemical Information and Modeling, vol. 59, no. 4, pp. 1584–1597, 2019.	2019
28	M. T. Khan, A. U. Rehaman, M. Junaid, S. I. Malik, and D.-Q. Wei, “Insight into novel clinical mutants of RPSA-S324F, E325K, and G341R of Mycobacterium tuberculosis associated with pyrazinamide resistance,” Computational and Structural Biotechnology Journal, vol. 16, pp. 379–387, 2018.	2018
29	A. Munir, S. I. Malik et al., “Medicinal plants are effective inhibitors of type I and II diabetes,” Pharmacophore, vol. 9, no. 5, pp. 1–7, 2018.	2018
30	M. Khan, S. Malik, A. Bhatti, S. Ali, A. Khan, M. Zeb, T. Nadeem, and S. Fazal, “Pyrazinamide-resistant Mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa and RPSA mutations,” J. Biol. Regul. Homeost. Agents, vol. 32, no. 3, pp. 705–709, 2018.	2018
31	M. Junaid, M. T. Khan, S. I. Malik, and D.-Q. Wei, “Insights into the mechanisms of the pyrazinamide resistance of three pyrazinamidase mutants N11K, P69T, and D126N,” Journal of Chemical Information and Modeling, vol. 59, no. 1, pp. 498–508, 2018.	2018
32	M. T. Khan, S. I. Malik, S. Ali, A. Sheed Khan, T. Nadeem, M. T. Zeb, N. Masood, and M. T. Afzal, “Prevalence of pyrazinamide resistance in Khyber Pakhtunkhwa, Pakistan,” Microbial Drug Resistance, vol. 24, no. 9, pp. 1417–1421, 2018.	2018
33	T. Khan, M. Malik, S. I. Malik, S. Fazal, A. Kaushik, M. Sharif, M. Irfan, M. Junaid, Wei DongQing, A. Bhatti, “Investigation of Mycobacterium tuberculosis oxidative stress pathway,” ACS Combinatorial Science, 2018.	2018
34	M. Junaid, M. T. Khan, S. I. Malik, and D.-Q. Wei, “Insights into the mechanisms of the pyrazinamide resistance of three pyrazinamidase mutants N11K, P69T, and D126N,” Journal of Chemical Information and Modeling, vol. 59, no. 1, pp. 498–508, 2018.	2018
35	M. N. Shahwani, S. Nisar, A. Aleem, M. Panezai, S. Afridi, and S. I. Malik, “Amplification of mitochondrial DNA for detection of Plasmodium vivax in Balochistan,” J Pak Med Assoc, vol. 67, no. 5, pp. 677–681, 2017.	2017
36	T. Noor, S. Zubair, M. Ismail, M. I. Khan, A. Gul, S. Iqbal, A. Mumtaz, and G. M. Murtaza, “Candidate genes prediction in Pakistani families with hearing impairment by using bioinformatic approach,” Biosci. J, vol. 28, no. 6, pp. 1024–1033, 2012.	2012
37	S. Kanwal, S. Nishat, M. I. Khan, S. I. Malik, and K. Akhtar, “Comparative homology modeling of human rhodopsin with several templates of bovine rhodopsin,” African Journal of Biotechnology, vol. 11, no. 2, pp. 466–473, 2012.	2012
38	Z. Khalid, S. Sameen, S. Malik, and S. Shehzad, “Computational analysis on the role of GPM6A in human thyroid cancer,” J Data Mining in Genom Proteomics, vol. 3, no. 1, p. 1000114, 2012.	2012
39	S. Malik and S. Khan, “Cancer prevention through employ of appropriate diet in daily schedule,” J Cancer Sci Ther, vol. 16, p. 17, 2011.	2011
40	V. Hatzi, G. Terzoudi, C. Stavropoulou, S. I. Malik, V. Makropoulos, and G. Pantelias, “Lack of association between GSTT1 polymorphism and endogenous or benzo [a] pyrene-induced sister chromatid exchanges as analyzed in metaphase or G2-phase lymphocytes,” Molecular Biology Reports, vol. 38, pp. 3959–3966, 2011.	2011
41	S. Sameen, Z. Khalid, and S. I. Malik, “Role of pyruvate dehydrogenase kinases (PDK’s) and their respective microRNA’s in human ovarian cancer,” J Med Genet Genomics, vol. 3, pp. 115–21, 2011.	2011
42	S. Malik I, Z. Khalid, S. Sameen, “In Silico Gene Expression Based Analysis on Claudine Family Members Association with Human Thyroid Cancer.” Journal of Proteomics and Bioinformatics, vol. 4, no. 12, pp. 278–283, 2011.	2011
43	A. D. Kligerman, S. I. Malik, and J. A. Campbell, “Cytogenetic insights into DNA damage and repair of lesions induced by a monomethylated trivalent arsenical,” Mutation Research/Genetic Toxicology and Environmental Mutagenesis, vol. 695, no. 1-2, pp. 2–8, 2010.	2010
44	S. Malik, G. Terzoudi, and G. Pantelias, “SCE analysis in G2 lymphocyte prematurely condensed chromosomes after exposure to atrazine: the non-dose-dependent increase in homologous recombinational events does not support its genotoxic mode of action,” Cytogenetic and Genome Research, vol. 104, no. 1-4, pp. 315–319, 2004.	2004
45	G. Terzoudi, S. Malik, G. Pantelias, K. Margaritis, K. Manola, and W. Makropoulos, “A new cytogenetic approach for the evaluation of mutagenic potential of chemicals that induce cell cycle arrest in the G2 phase,” Mutagenesis, vol. 18, no. 6, pp. 539–543, 2003.	2003
46	K. Manola, G. Terzoudi, C. Dardoufas, S. Malik, and G. Pantelias, “Radioprotective effect of amifostine on cells from cancer prone patients and healthy individuals studied by the G2 and PCC assays,” International Journal of Radiation Biology, vol. 79, no. 10, pp. 831–838, 2003.	2003

SR.	CONFERENCE PUBLICATIONS	YEAR
1	A. Munir, S. I. Malik, and K. A. Malik, “De-novo ligand design against mutated huntington gene by ligand-based pharmacophore modeling approach,” Current Computer-Aided Drug Design, vol. 16, no. 2, pp. 134–144, 2020.	2020
2	A. Munir, S. I. Malik, “Proteome mining for the identification of putative drug targets for human pathogen clostridium tetani,” Current Bioinformatics, vol. 14, no. 6, pp. 532–540, 2019.	2019
3	M. T. Khan, S. I. Malik, S. Ali, N. Masood, T. Nadeem, A. S. Khan, and M. T. Afzal, “Pyrazinamide resistance and mutations in pnca among isolates of mycobacterium tuberculosis from khyber pakhtunkhwa, pakistan,” BMC infectious diseases, vol. 19, pp. 1–7, 2019.	2019
4	M. T. Khan, S. I. Malik, S. Ali, A. Sheed Khan, T. Nadeem, M. T. Zeb, N. Masood, and M. T. Afzal, “Prevalence of pyrazinamide resistance in khyber pakhtunkhwa, pakistan,” Microbial Drug Resistance, vol. 24, no. 9, pp. 1417–1421, 2018.	2018
5	F. Nazir, S. Malik, S. Fazal, M. Ullah, A. Bhatti ”Manuscript entitled: Elastic network modelling of E7 protein of Human Papilloma Virus and prediction of host proteins affected by E7”. VIRUS 2018 151: Corresponding author: Mrs Rabbiah Malik, 2018.	2018
6	M. Khan, M. Junaid, S. I. Malik, D. Wei, “Pyrazinamide resistance and Mutations L19R, R140H and E144K in pncA of Mycobacterium tuberculosis” by Submitted manuscript ID number JCB-18-1370, 2018.	2018
7	Z. Khalid, S. Sameen, and S. I. Malik, “In silico mining of RAS gene family expression data in human thyroid cancer,” in 2011 5th International Conference on Bioinformatics and Biomedical Engineering. IEEE, 2011, pp. 1–4.	2011

Our Team

Dr. Shaukat Iqbal

PROFILE SUMMARY

Other Members